



## Complete Summary

---

### TITLE

Menopause and hormone therapy (HT): collaborative decision-making and management: the percentage of women in menopause who have had a bone mineral density (BMD) measurement a year after cessation of HT.

### SOURCE(S)

Institute for Clinical Systems Improvement (ICSI). Menopause and hormone therapy (HT): collaborative decision-making and management. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2006 Oct. 63 p. [195 references]

## Measure Domain

### PRIMARY MEASURE DOMAIN

Process

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the [Measure Validity](#) page.

### SECONDARY MEASURE DOMAIN

Does not apply to this measure

## Brief Abstract

### DESCRIPTION

This measure is used to assess the percentage of women in menopause who have had a bone mineral density (BMD) measurement a year after cessation of hormone therapy (HT).

### RATIONALE

The priority aim addressed by this measure is to increase the percentage of women with appropriate follow-up to cessation of hormone therapy (HT).

### PRIMARY CLINICAL COMPONENT

Menopause; hormone therapy (HT); bone mineral density (BMD) measurement

**DENOMINATOR DESCRIPTION**

Total number of women in the medical group's practice in menopause who have discontinued hormone therapy (HT) (see the related "Denominator Inclusions/Exclusions" field in the Complete Summary)

**NUMERATOR DESCRIPTION**

Number of women in menopause receiving a bone mineral density (BMD) measurement a year after cessation of hormone therapy (HT)

**Evidence Supporting the Measure**

**EVIDENCE SUPPORTING THE CRITERION OF QUALITY**

- A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

**NATIONAL GUIDELINE CLEARINGHOUSE LINK**

- [Menopause and hormone therapy \(HT\): collaborative decision-making and management.](#)

**Evidence Supporting Need for the Measure**

**NEED FOR THE MEASURE**

Unspecified

**State of Use of the Measure**

**STATE OF USE**

Current routine use

**CURRENT USE**

Internal quality improvement

**Application of Measure in its Current Use**

**CARE SETTING**

Physician Group Practices/Clinics

**PROFESSIONALS RESPONSIBLE FOR HEALTH CARE**

Physicians

**LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED**

Group Clinical Practices

**TARGET POPULATION AGE**

Unspecified

**TARGET POPULATION GENDER**

Female (only)

**STRATIFICATION BY VULNERABLE POPULATIONS**

Unspecified

**Characteristics of the Primary Clinical Component****INCIDENCE/PREVALENCE**

More women than ever before will be entering menopause as the "baby boomer" generation ages. By the year 2020, the number of perimenopausal women will almost double, to 40 million.

**EVIDENCE FOR INCIDENCE/PREVALENCE**

Institute for Clinical Systems Improvement (ICSI). Menopause and hormone therapy (HT): collaborative decision-making and management. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2006 Oct. 63 p. [195 references]

**ASSOCIATION WITH VULNERABLE POPULATIONS**

Unspecified

**BURDEN OF ILLNESS**

Unspecified

**UTILIZATION**

Unspecified

**COSTS**

Unspecified

## Institute of Medicine National Healthcare Quality Report Categories

### IOM CARE NEED

Living with Illness

### IOM DOMAIN

Effectiveness

## Data Collection for the Measure

### CASE FINDING

Users of care only

### DESCRIPTION OF CASE FINDING

Women who are in menopause and have discontinued hormone therapy (HT).

Select a randomized sample of the eligible population for data collection. The suggested sample size for each medical group is at least 10 charts each month.

The medical record of each woman is reviewed to determine if the woman is in menopause and had discontinued HT.

The suggested time frame for data collection is a calendar month.

### DENOMINATOR SAMPLING FRAME

Patients associated with provider

### DENOMINATOR INCLUSIONS/EXCLUSIONS

#### Inclusions

Total number of women in the medical group's practice\* in menopause\*\* who have discontinued hormone therapy (HT)

\*"In the medical group practice" is defined as a woman who has been seen two or more times by the medical group (including office visits and urgent care).

\*\*A woman is diagnosed as having menopause if 1) she has had complete cessation of menses for one year, 2) premature menopause, or 3) surgical-, chemotherapy-, or radiation-induced menopause, or 4) if younger than average, or continuation of regular menses, and has a positive follicle stimulating hormone (FSH) and/or estradiol lab test. This would correspond to patients with diagnosis codes 627.x and 256.31 and Current Procedure Terminology (CPT) codes 80418, 80426, and/or 82670.

#### Exclusions

Unspecified

## **RELATIONSHIP OF DENOMINATOR TO NUMERATOR**

All cases in the denominator are equally eligible to appear in the numerator

## **DENOMINATOR (INDEX) EVENT**

Clinical Condition  
Therapeutic Intervention

## **DENOMINATOR TIME WINDOW**

Time window follows index event

## **NUMERATOR INCLUSIONS/EXCLUSIONS**

### **Inclusions**

Number of women in menopause receiving a bone mineral density (BMD) measurement a year after cessation of hormone therapy (HT)

### **Exclusions**

Unspecified

## **MEASURE RESULTS UNDER CONTROL OF HEALTH CARE PROFESSIONALS, ORGANIZATIONS AND/OR POLICYMAKERS**

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

## **NUMERATOR TIME WINDOW**

Episode of care

## **DATA SOURCE**

Administrative data  
Medical record

## **LEVEL OF DETERMINATION OF QUALITY**

Individual Case

## **PRE-EXISTING INSTRUMENT USED**

Unspecified

## **Computation of the Measure**

## **SCORING**

Rate

**INTERPRETATION OF SCORE**

Better quality is associated with a higher score

**ALLOWANCE FOR PATIENT FACTORS**

Unspecified

**STANDARD OF COMPARISON**

Internal time comparison

Evaluation of Measure Properties

**EXTENT OF MEASURE TESTING**

Unspecified

Identifying Information

**ORIGINAL TITLE**

The percentage of women in menopause who have had a bone mineral density (BMD) measurement a year after cessation of HT.

**MEASURE COLLECTION**

[Menopause and Hormone Therapy \(HT\): Collaborative Decision-Making and Management Measures](#)

**DEVELOPER**

Institute for Clinical Systems Improvement

**ADAPTATION**

Measure was not adapted from another source.

**RELEASE DATE**

2004 Oct

**REVISION DATE**

2006 Oct

## **MEASURE STATUS**

This is the current release of the measure.

This measure updates a previous version: Institute for Clinical Systems Improvement (ICSI). Menopause and hormone therapy (HT): collaborative decision-making and management. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2005 Aug. 64 p.

## **SOURCE(S)**

Institute for Clinical Systems Improvement (ICSI). Menopause and hormone therapy (HT): collaborative decision-making and management. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2006 Oct. 63 p. [195 references]

## **MEASURE AVAILABILITY**

The individual measure, "The percentage of women in menopause who have had a bone mineral density (BMD) measurement a year after cessation of HT," is published in "Health Care Guideline: Menopause and Hormone Therapy (HT): Collaborative Decision-Making and Management." This document is available from the [Institute for Clinical Systems Improvement \(ICSI\) Web site](#).

For more information, contact ICSI at, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; phone: 952-814-7060; fax: 952-858-9675; Web site: [www.icsi.org](http://www.icsi.org); e-mail: [icsi.info@icsi.org](mailto:icsi.info@icsi.org).

## **NQMC STATUS**

This NQMC summary was completed by ECRI on January 19, 2005. This NQMC summary was updated by ECRI on October 25, 2005 and again on December 11, 2006.

## **COPYRIGHT STATEMENT**

This NQMC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Measure) is based on the original measure, which is subject to the measure developer's copyright restrictions.

The abstracted ICSI Measures contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Measures are downloaded by an individual, the individual may not distribute copies to third parties.

If the abstracted ICSI Measures are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.

All other copyright rights in the abstracted ICSI Measures are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems

Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Measures.

## Disclaimer

### **NQMC DISCLAIMER**

The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at

<http://www.qualitymeasures.ahrq.gov/about/inclusion.aspx>.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. The inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.

© 2008 National Quality Measures Clearinghouse

Date Modified: 11/3/2008

